Ori Shilo - RedHill Biopharma Co-Founder and Deputy CEO of Fin. and Operations
CEO
Mr. Ori Shilo serves as Deputy Chief Executive Officer Finance and Operations Director of Redhill Biopharma Ltd. Ori has financial and transactional experience. He was previously with ProSeed Capital the Israeli Antitrust Authority and Delloite Touche Consulting. Ori received an MBA from Ben Gurion University and a B.A. in Business Administration from the College of Management TelAviv. since 2012.
| Age | 47 |
| Tenure | 12 years |
| Professional Marks | MBA |
| Phone | 972 3 541 3131 |
| Web | http://www.redhillbio.com |
RedHill Biopharma Management Efficiency
The company has return on total asset (ROA) of (32.82) % which means that it has lost $32.82 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (246.27) %, meaning that it generated substantial loss on money invested by shareholders. RedHill Biopharma's management efficiency ratios could be used to measure how well RedHill Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 85.89 M in total debt with debt to equity ratio (D/E) of 2.99, implying the company greatly relies on financing operations through barrowing. RedHill Biopharma has a current ratio of 1.76, which is within standard range for the sector. Debt can assist RedHill Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, RedHill Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like RedHill Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for RedHill to invest in growth at high rates of return. When we think about RedHill Biopharma's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 10 records | CEO Age | ||
| James Rourke | The Mosaic | 54 | |
| Anthony Will | CF Industries Holdings | 58 | |
| W Will | CF Industries Holdings | 55 | |
| Christopher Constant | Getty Realty | 45 | |
| Patrick Hawkins | Hawkins | 53 | |
| Paul Manning | Sensient Technologies | 49 | |
| James ORourke | The Mosaic | 60 | |
| Carlos Souza | Braskem SA Class | N/A | |
| Roberto Simoes | Braskem SA Class | 67 | |
| Mark Nikolich | Braskem SA Class | N/A | |
Management Performance
| Return On Equity | -246.27 | |||
| Return On Asset | -32.82 |
RedHill Biopharma Leadership Team
Elected by the shareholders, the RedHill Biopharma's board of directors comprises two types of representatives: RedHill Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of RedHill. The board's role is to monitor RedHill Biopharma's management team and ensure that shareholders' interests are well served. RedHill Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, RedHill Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Patricia Anderson, Vice President - Regulatory Affairs | ||
| Micha Chorin, CFO | ||
| Ofer Tsimchi, Director | ||
| Patrick Mclean, Product Manager | ||
| Aida Bibliowicz, Vice President - Clinical Affairs Europe | ||
| Ori Shilo, Co-Founder and Deputy CEO of Fin. and Operations | ||
| Shmuel Cabilly, Director | ||
| Dror BenAsher, Chairman of the Board, CEO | ||
| Rob Jackson, Vice President of Marketing | ||
| Kenneth Reed, Director | ||
| Elkan Gamzu, Product Manager | ||
| Robert Gilkin, Vice President of Market Access | ||
| Adi Frish, Sr. VP of Bus. Devel. and Licensing | ||
| Steven Thomasian, Vice President of Supply Chain | ||
| Guy Goldberg, Chief Business Officer | ||
| Reza Fathi, Sr. VP of RandD | ||
| Tom Lang, Vice President - Regulatory & Clinical Affairs | ||
| Clara Fehrmann, Product Manager | ||
| Pascal Weerts, Director - Corporate and Legal Affairs | ||
| Eric Swenden, Director | ||
| Dan Suesskind, Director | ||
| Gilead Raday, Senior Vice President - Product and Corporate Development | ||
| Rick Scruggs, Director | ||
| Terry Plasse, Medical Director | ||
| Danielle Abramson, Director - Intellectual Property & Research | ||
| Uri Aharon, Chief Accounting Officer | ||
| Shani Maurice, Vice President - Business Development & Communications | ||
| Patricia Bandeira, Product Manager - Oncology | ||
| Ira Kalfus, Medical Director | ||
| Nurit Benjamini, External Director |
RedHill Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is RedHill Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -246.27 | |||
| Return On Asset | -32.82 | |||
| Profit Margin | (142.81) % | |||
| Operating Margin | (123.49) % | |||
| Current Valuation | 76.08 M | |||
| Shares Outstanding | 234.96 M | |||
| Shares Owned By Insiders | 4.94 % | |||
| Shares Owned By Institutions | 0.20 % | |||
| Price To Earning | (4.01) X | |||
| Price To Book | 0.87 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards RedHill Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, RedHill Biopharma's short interest history, or implied volatility extrapolated from RedHill Biopharma options trading.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in RedHill Pink Sheet
If you are still planning to invest in RedHill Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RedHill Biopharma's history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Stocks Directory Find actively traded stocks across global markets |